Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling

被引:27
作者
Jung, Kwan-Young [1 ]
Samadani, Ramin [1 ]
Chauhan, Jay [1 ]
Nevels, Kerrick [1 ]
Yap, Jeremy L. [1 ]
Zhang, Jun [1 ]
Worlikar, Shilpa [1 ]
Lanning, Maryanna E. [1 ]
Chen, Lijia [1 ]
Ensey, Mary [2 ]
Shukla, Sagar [1 ]
Salmo, Rosene [3 ]
Heinzl, Geoffrey [1 ]
Gordon, Caryn [4 ]
Dukes, Troy [5 ]
MacKerell, Alexander D., Jr. [1 ,6 ]
Shapiro, Paul [1 ,6 ]
Fletcher, Steven [1 ,6 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA
[2] Notre Dame Maryland Univ, Baltimore, MD 21212 USA
[3] Indiana Univ Purdue Univ, Indianapolis, IN 46202 USA
[4] Univ Maryland, College Pk, MD 20742 USA
[5] Antioch Diploma Plus High Sch, Baltimore, MD 21218 USA
[6] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
基金
美国国家卫生研究院;
关键词
TYROSINE KINASE INHIBITORS; RAF/MEK/ERK PATHWAY; MAP KINASES; RESISTANCE; CANCER; BRAF; MUTATIONS; DISCOVERY; DOMAIN; GENE;
D O I
10.1039/c3ob40199e
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
We herein report on the pharmacophore determination of the ERK docking domain inhibitor (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione, which has led to the discovery of compounds with greater selectivities for inhibiting the proliferation of melanoma cells containing active ERK signaling.
引用
收藏
页码:3706 / 3732
页数:27
相关论文
共 47 条
[1]   Development of farnesyl transferase inhibitors: A review [J].
Appels, NMGM ;
Beijnen, JH ;
Schellens, JHM .
ONCOLOGIST, 2005, 10 (08) :565-578
[2]   Flipped out: Structure-guided design of selective pyrazolylpyrrole ERK inhibitors [J].
Aronov, Alex M. ;
Baker, Christopher ;
Bemis, Guy W. ;
Cao, Jingrong ;
Chen, Guanjing ;
Ford, Pamella J. ;
Germann, Ursula A. ;
Green, Jeremy ;
Hale, Michael R. ;
Jacobs, Marc ;
Janetka, James W. ;
Maltais, Francois ;
Martinez-Botella, Gabriel ;
Namchuk, Mark N. ;
Straub, Judy ;
Tang, Qing ;
Xie, Xiaoling .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (06) :1280-1287
[3]   Role of tyrosine kinase inhibitors in cancer therapy [J].
Arora, A ;
Scholar, EM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :971-979
[4]  
BOS JL, 1989, CANCER RES, V49, P4682
[5]   Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9 [J].
Boston, Sarice R. ;
Deshmukh, Rahul ;
Strome, Scott ;
Priyakumar, U. Deva ;
MacKerell, Alexander D., Jr. ;
Shapiro, Paul .
BMC CANCER, 2011, 11
[6]  
Brose MS, 2002, CANCER RES, V62, P6997
[7]   Development of Extracellular Signal-Regulated Kinase Inhibitors [J].
Burkhard, Kimberly ;
Smith, Sarice ;
Deshmukh, Rahul ;
MacKerell, Alexander D., Jr. ;
Shapiro, Paul .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (08) :678-689
[8]   Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure [J].
Chen, Fengming ;
Hancock, Chad N. ;
Macias, Alba T. ;
Joh, Joseph ;
Still, Kimberly ;
Zhong, Shijun ;
MacKerell, Alexander D., Jr. ;
Shapiro, Paul .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) :6281-6287
[9]  
Chen RH, 1996, ONCOGENE, V12, P1493
[10]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954